Topiramate-induced psychosis in patients with essential tremor: Report of 2 cases

Clinical Neuropharmacology

Volumn 29, Issue 3, 2006, Pages 168-169

  Zesiewicz, Theresa A ^a,b,c,e   Tullidge, Archer ^d   Tidwell, Jonathan ^d   Sullivan, Kelly L ^a,b,c   Hauser, Robert A ^a,b,c  

^a Parkinson's Disease and Movement Disorders Center   (United States)

^b Department of Neurology ^*  (United States)

^c National Parkinson's Foundation Center of Excellence   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Essential tremor; Hallucinations; Psychosis; Topamax; Topiramate

Indexed keywords

PRIMIDONE; PROPRANOLOL; TOPIRAMATE; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; ESSENTIAL TREMOR; HUMAN; HYPOTENSION; LOW DRUG DOSE; MALE; NEUROLOGIC EXAMINATION; PARANOIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSIS; SOMNOLENCE; TREATMENT WITHDRAWAL; VISUAL HALLUCINATION; VIVID DREAM; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ESSENTIAL TREMOR; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 33746441193     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000220823.80640.44     Document Type: Article

References (14)

1. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg dosages. Neurology 1996;46:1684-1690.
2. Marcotte D. Use of topiramate, a new anti-epileptic, as a mood stabilizer. J Affect Disord 1998;50:245-251.
3. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-1033.
4. Calabrese JR. Update on the use of topiramate in bipolar disorder. Am Psychiat Assoc 2000;44S:13-18. [Abstract].
5. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial. Part 2: improvement in psychiatric measures. J Clin Psychiatry 2003;64:1449-1454.
6. Cassano P, Lattanzi L, Pini S, et al. Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord 2001;3:161. [letter].
7. Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor. Neurology. March 2006;66:672-677.
8. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993;24:414-452.
9. Mula M, Trimble MR. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-663.
10. Khan A, Fauaght E, Gillian F, et al. Acute psychotic symptoms induced by topiramate. Seizure 1999;84:235-237.
11. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? J Clin Psychiatry 2004;65:1145.
12. Drapalski AL, Rosse RB, Peebles RR, et al. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24:290-294.
13. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002;63:1045. [letter].
14. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 1993;92(1):57-65.